Liquidia Corporation: From Treprostinil Pioneer to Highly Profitable Pharma Player

Liquidia utilizes its patented PRINT® platform to transform established active ingredients like Treprostinil into the high-dose dry powder YUTREPIA®, thereby significantly simplifying the treatment of pulmonary hypertension. With the launch of YUTREPIA®, the company has successfully transitioned from a loss-making research firm to a profitable specialty pharmaceutical company with revenues in the triple-digit millions. Through advancements in the PH-ILD market, studies for new patient groups, and the development of the L606 formula, Liquidia...